Table 2.
Summary of AEs related to treatment
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total | |
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| AE related to treatment | ||||||
| Overall frequency | 6 (12%) | 16 (33%) | 11 (22%) | 1 (2%) | 0 (0%) | 34 (69%) |
| Brain edema | 2 (4%) | 8 (16%) | 7 (14%) | 1 (2%) | 0 (0%) | 18 (37%) |
| Headache | 4 (8%) | 9 (18%) | 2 (4%) | 0 (0%) | 0 (0%) | 15 (31%) |
| Fatigue | 7 (14%) | 7 (14%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 (29%) |
| Dysphasia | 4 (8%) | 4 (8%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (16%) |
| Hemiparesis | 0 (0%) | 2 (4%) | 4 (8%) | 0 (0%) | 0 (0%) | 6 (12%) |
| Pyrexia | 5 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (10%) |
| Decreased appetite | 3 (6%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (8%) |
| Myalgia | 2 (4%) | 2(4%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (8%) |
| Nausea | 2 (4%) | 2(4%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (8%) |
| SAE related to treatment | ||||||
| Overall frequency | 0 (0%) | 4 (8%) | 9 (18%) | 1 (2%) | 0 (0%) | 14 (29%) |
| Brain/vasogenic edema | 0 (0%) | 1 (2%) | 6 (12%) | 1 (2%) | 0 (0%) | 8 (16%) |
| Dysphasia | 0 (0%) | 3 (6%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (6%) |
| Hemiparesis | 0 (0%) | 0 (0%) | 3 (6%) | 0 (0%) | 0 (0%) | 3 (6%) |
AE denotes adverse event. SAE denotes serious adverse event. Shown are AEs and SAEs with greater than 5% frequency. Overall frequency refers to patients reporting at least one treatment related AE. Each patient is included once using the highest-grade event. Events were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events, version 4.03.